Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Well-tolerated with fewer reported side effects compared to other peptides
Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
Abrao et al
Withanolides are naturally occurring steroidal lactones derived from an ergostane framework, and their structural diversity, arising from variations in oxidation, hydroxylation, and glycosylation, underlies their multitarget biological effects
Sie erfordern vertiefte Kenntnisse der Prozesse und Ablufe sowie der Regelwerke und gesetzlichen Vorgaben, die eingehalten werden mssen
